La Jolla’s Giapreza Reports First COVID Sales Figures
Insights - La Jolla (LJPC) released Q1 numbers today. Although we were expecting a larger jump, as a result of the COVID situation and increase in demand … Continue Reading
PremiumSearch Results for "priority review voucher"
Fennec’s NDA Checks Out. PDUFA on August 10th
Insights - This morning Fennec announced that the FDA accepted their NDA for Pedmark and granted the company Priority Review. The PDUFA has been set for August 10, 2020. … Continue Reading
PremiumSubmissions to FDA & EMA Position Fennec For Big 2020
Insights - This morning Fennec (FENC) announced that the company completed their NDA filing to FDA & application to EMA (read here). Surprising EMA SubmissionEuropean submission was a pleasant surprise, as … Continue Reading
PremiumLa Jolla Rallying After Chairman Tang Bets Additonal $17M in Turnaround
Insights - La Jolla has been on a tear in the new year and since we first covered the name in early December at a price around … Continue Reading
PremiumCommercial Giapreza Makes La Jolla A Contrarian Play
Insights - La Jolla Pharma (LJPC) is a beat up contrarian play that has dropped roughly 70% since September. Why? Because: (1) Commercial launch of Giapreza has … Continue Reading
Premium
Amicus Therapeutics Does Some Acquiring of its Own
Insights - Amicus Therapeutics (FOLD), long implicated as an acquisition target by its investors, will do some acquiring of its own. Amicus announced early Monday that it will buy … Continue Reading
Read now
